share_log

ADC Therapeutics Q3 Adj. EPS $(0.41) Beats $(0.63) Estimate, Sales $14.49M Miss $15.99M Estimate

Benzinga ·  11/07/2023 20:13

ADC Therapeutics (NYSE:ADCT) reported adjusted quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.63) by 34.92 percent. This is a 415.38 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $14.49 million which missed the analyst consensus estimate of $15.99 million by 9.36 percent. This is a 81.01 percent decrease over sales of $76.32 million the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment